Dr. Zhiwei Hu

College of Medicine Ohio State University, USA

Associate Professor

Email: [email protected]

Qualifications

1997  Ph.D., Tumor Immunobiology, Hunan Medical University, China

1994  M.S., Tumor Immunology, Jiangxi Medical College, China

1991  M.D., Medicine and Stomatology, Jiangxi Medical College, China

Publications(Selected)

1. Hu Z, Wu J, Yang Q, Jomard F, Granberg F, Barthe M F, et al. New insight into the quantifying vacancy distribution in self-ion-irradiated tungsten: a combined experimental and computational study. Nano Letters, 25(27):10787-10793, 2025.

2. Mamillapalli R, Krikun G, Nimisha G, Hu Z, Taylor H S. TF-CAR-NK cells as an immunotherapy for endometriosis. Reproductive Sciences, 32(1):52A-52A, 2025.
3. Ancel J, Bergantini L, Mendogni P, Hu Z. Thoracic malignancies: from prevention and diagnosis to late stages. Life, 15(2):138, 2025.
4. Hu Z, Bousbaa H. Recent advances in anticancer strategies. Cancers, 17(2):173, 2025.
5. Hu Z, Yang Q, Jomard F, Desgardin P, Genevois C, Joseph J, Olsson P, et al. Revealing the role of oxygen on the defect evolution of electron-irradiated tungsten: a combined experimental and simulation study. Journal of Nuclear Materials, 602:155353, 2024.
6. Wu J, Balbuena J P, Hu Z, Jantunen V, Barthe M F, Caturla M J, Granberg F. High-dose long-time defect evolution in tungsten studied by atomistically informed object kinetic Monte Carlo simulations. arXiv preprint arXiv:2409.15856, 2024.
7. Hu Z. Vacancy defects distribution in self-ion irradiated molybdenum. Scientific Books of Abstracts, 4:21-21, 2024.
8. Lai E, Ziranu P, Pezzella F, Pretta A, Liscia N, Hu Z. Angiogenesis and access to vasculature as a target in gastrointestinal tumors and predictive biomarkers identification: an open challenge. Frontiers in Oncology, 14:1428174, 2024.
9. Hu Z. Methods and compositions related to a tissue factor-targeting IgG3 immunoconjugates. US Patent App. 18/529,638, 2024.
10. Hu Z. Methods and compositions related to a tissue factor-targeting IgG3 immunoconjugates. US Patent 11,872,194, 2024.
11. Meng L, Collier K A, Wang P, Monk P, Mortazavi A, Hu Z, et al. Emerging immunotherapy approaches for advanced clear cell renal cell carcinoma. Cells, 13(1):34, 2023.
12. Wang H, Zhang H, Wang Y, Brown Z J, Xia Y, Huang Z, Shen C, Hu Z, et al. Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis. Journal of Hepatology, 75(6):1271-1283, 2021.
13. Zhang H, Wang Y, Onuma A, He J, Wang H, Xia Y, Lal R, Cheng X, et al. Neutrophils extracellular traps inhibition improves PD-1 blockade immunotherapy in colorectal cancer. Cancers, 13(21):5333, 2021.
14. Ren J, He J, Zhang H, Xia Y, Hu Z, Loughran P, Billiar T, Huang H, et al. Platelet TLR4-ERK5 axis facilitates NET-mediated capturing of circulating tumor cells and distant metastasis after surgical stress. Cancer Research, 81(9):2373-2385, 2021.
15. Hu Z. Using CAR-NK cells to overcome the host resistance to antibody immunotherapy and immune checkpoint blockade therapy. In: Successes and Challenges of NK Immunotherapy, 193-212, 2021.
16. Hufnagel D, Goetz L G, Hu Z, Nyachieo A, D’Hooghe T, Fazleabas A, et al. Corrigendum to “Icon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio anubis) model of endometriosis”. Reproductive Biology, 20(4):600, 2020.
17. Gomez S, Tsung A, Hu Z. Current targets and bioconjugation strategies in photodynamic diagnosis and therapy of cancer. Molecules, 25(21):4964, 2020.
18. Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Scientific Reports, 10(1):2815, 2020.

Personal Details

https://cancer.osu.edu/find-a-researcher/search-researcher-directory/zhiwei-hu-100003209

https://scholar.google.com/citations?user=xOM1_3wAAAAJ&hl=en

https://www.researchgate.net/profile/Zhiwei-Hu-4

WoS Researcher ID: AFO-5036-2022